

„SAFER EUROPE WITHOUT FALSIFIED MEDICINES” – conference during the Estonian Presidency of the EU Council

November 8–9, 2017 at Kultuurikatel, Tallinn, Estonia

Final agenda

	Theme	Organization	Discussion topics	Chair and speakers
DAY 1				
12.00	Registration and coffee			
13.00–13.30	Opening session Setting the Scene	Estonian Ministry of Social Affairs EU Commission	<ul style="list-style-type: none"> – Welcome – Situation with the falsified medicines in the world and in Europe – Overview of the requirements in EU – Benefits for the patients 	<p>Mr Jevgeni Ossinovski, Estonian Minister of Health and Labour</p> <p>Ms Maris Jesse, Deputy Secretary General of the Ministry of Social Affairs of Estonia</p> <p>Keynote address: Mr Andrzej Rys, Director of Health Systems and Products DG SANTE, European Commission</p>
13.30–15.00	I session European and National Medicines Verification Organizations – state of play	EMVO NMVOs	<ul style="list-style-type: none"> – EMVO – what is the status – Overview of NMVOs, Estonian experience – Repositories – central HUB, national repositories, what is ready, what is under development, what data is available to whom 	<p>Chair: Mr Andreas Walter, General Manager, EMVO</p> <p>Speakers: Mr Raul Mill, Chief Executive, REKS</p> <p>Ms Maija Gohlke-Kokkonen, Executive Director, FiMVO</p> <p>Ms Leonie Clarke, Project Manager, IMVO</p> <p>Ms Illiana Paunova, Executive Director, BgMVO</p>
15.00	Coffee break			

15.30–17.00	II session Developers of the new system – their challenges in setting up data repositories	EU stakeholders and EMVO	– View of stakeholders: Manufacturers (EFPIA, Medicines for Europe, EAEPIC) Wholesalers (GIRP) Pharmacies (PGEU)	Chair: Mr Per Troein , VP Strategic Partners QuintilesIMS Speakers: Ms Monika Derecque-Pois , Director General, GIRP Mr Richard Freudenberg , Chief Executive, EAEPIC Mr Michael Rose , Vice President, Supply Chain Visibility, Johnson & Johnson and Chair of EFPIA's Supply Chain Ms Jurate Svarcaite , Secretary General, PGEU Mr Adrian van den Hoven , Director General, Medicines for Europe <i>5 minutes each presenter, panel discussion</i>
17.00–17.30	Coffee break			
17.30–18.30	III session Challenges of implementing hospitals within NMVS	FAMHP, HOPE, EAHP, EMVO	Panel discussion	Chair: Mr Philippe De Buck , FAMHP Mr Pascal Garel , Chief Executive, HOPE Ms Stephanie Kohl , Policy Officer, EAHP Mr Hugh Pullen , Chairman, EMVO
18.30–21.00	Reception followed by the dinner			

DAY 2				
9.00–10.30	<p>IV session Implementing by the Member States – timetable and challenges</p> <p>How to get more value – future developments – additional applications – is it possible?</p>	<p>HMA – Heads of Medicine Agencies</p> <p>EMVO stakeholders</p>	<p>– National requirements – ATD (Anti-tampering Device) on OTC products, extension of the requirement of safety features, multi-market packs vs potential inclusion of national reimbursement numbers in data matrix codes, update of marketing authorization files</p> <p>– Supervision of repositories – who is responsible for what</p> <p>– National Competent Authorities’ (NCA) access to data contained in repositories</p>	<p>Chair: Ms Belén Escribano Romero, Head of the Pharmaceutical Inspection and Enforcement Department at AEMPS</p> <p>Speakers:</p> <p>Mr Michael Rose, Vice President, Supply Chain Visibility, Johnson & Johnson and Chair of EFPIA’s Supply Chain</p> <p>Ms Jurate Svarcaite, Secretary General, PGEU</p> <p>Ms Monika Derecque-Pois, Director General, GIRP</p> <p>Ms Jan MacDonald, Head Patient Information Quality, MHRA</p> <p>Ms Agnès Mathieu-Mendes, Deputy Head, DG SANTE, European Commission</p>
10.30	Coffee break			
11.00–12.00	<p>V session Availability of medicinal products after Feb 2019</p>	<p>Estonian State Agency of Medicines (SAM)</p> <p>EMVO stakeholders</p>	<p>– How do Member States intend to use the data contained in repositories?</p> <p>– To what extent the setting up of EMVS (European Medicines Verification System) would impact availability?</p> <p>– Will the situation with the availability of medicines worsen or improve?</p>	<p>Chair:</p> <p>Ms Kristin Raudsepp, Director General, Estonian State Agency of Medicines</p> <p>Speakers:</p> <p>Mr Adrian van den Hoven, Director General, Medicines for Europe</p> <p>Mr Richard Freudenberg, Chief Executive, EAEP</p> <p>Ms Stephanie Kohl, Policy Officer, EAHP</p>

12.00–13.00	<p>Panel session Is Europe ready?</p>		<p>– Identification of key priority issues for progressing implementation and recommendations for action – Conclusions of the conference</p>	<p>Moderator: Ms Agnès Mathieu-Mendes, B4, Deputy Head, DG SANTE, European Commission Panellist: Mr Andreas Walter, General Manager, EMVO Ms Anci Kvarnström, CEO, PhQConsulting AB, NMVO Sweden</p>
13.00–14.00	Lunch			